Accelerating your Product’s Journey from Lab to Patient,
with Improved Model Platforms
The past year has seen many immunotherapies as monotherapies and combination regimes gain FDA and EMA approval, particularly in targeting solid and rarer tumour types. Alongside this, the FDA Modernization Act 2.0 passing has also brought huge excitement to the field, inspiring preclinical and translational tumour model experts to continue pushing to improve success rates in the clinic.
At the 12th Annual Tumour Models London Summit, you will gain practical insights into the latest updates through 20+ case studies that will empower your candidate selection workflows. Join us to learn from and meet pioneers in preclinical and translational oncology to accelerate your product’s journey from lab to patient with optimized translatability, efficiency, and cost-effectiveness!
A Snapshot of What to Expect This Year:
AstraZeneca, Ichnos Science, Breakpoint Therapeutics, and more reveal their model selection criteria dependent on cancer type to enable you to streamline your model selection process
Unravel the complexities of modelling the tumour microenvironment to empower combination therapy studies with Marc van Dijk, Chief Scientific Officer, MiNK Therapeutics
Candel Therapeutics demonstrates techniques to engineer mouse models to efficiently study oncolytic viruses/CAR-T combination therapy
Explore bone marrow microphysiological systems to optimise dosing regimens and predict clinical outcomes with Kainat Khan, Associate Director, Oncology Safety Science, AstraZeneca
Prokarium uncovers strategies for effective collaborations with CROs to develop tumour models for immunotherapy studies
Expert Speakers Include
Our Expert Partners
Other Events in the Series:
